NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Wednesday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO stock opened at $3.93 on Wednesday. The stock has a 50 day simple moving average of $3.65 and a 200-day simple moving average of $3.84. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $5.96. The company has a market cap of $7.90 million, a price-to-earnings ratio of -0.62 and a beta of 2.28.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The company had revenue of $0.77 million for the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.